inotiv-logo.png
Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update
15 mai 2024 16h05 HE | Inotiv, Inc.
— Second quarter fiscal 2024 revenue down 21.5% to $119.0 million— Year-to-date fiscal 2024 revenue down 7.2% to $254.5 million— Agreement in principle reached with the U.S. Department of Justice on...
inotiv-logo.png
Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Wednesday, May 15, 2024
14 mai 2024 07h00 HE | Inotiv, Inc.
WEST LAFAYETTE, Ind., May 14, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical...
inotiv-logo.png
Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results
09 mai 2024 18h56 HE | Inotiv, Inc.
WEST LAFAYETTE, Ind., May 09, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery...
inotiv-logo.png
Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Friday, May 10, 2024
29 avr. 2024 16h05 HE | Inotiv, Inc.
WEST LAFAYETTE, Ind., April 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical...
inotiv-logo.png
Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update
07 févr. 2024 16h05 HE | Inotiv, Inc.
- First quarter fiscal 2024 revenue up 10.3% to $135.5 million - First quarter fiscal 2024 DSA revenue up 8.8% to $44.7 million and RMS revenue up 11.1% to $90.8 million - Shift to a renewed focus...
inotiv-logo.png
Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024
29 janv. 2024 16h05 HE | Inotiv, Inc.
WEST LAFAYETTE, Ind., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical...
inotiv-logo.png
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update
11 déc. 2023 16h05 HE | Inotiv, Inc.
— Fiscal year 2023 revenue up 4.5% to $572.4 million, achieving full year revised guidance— Achievements in the past fiscal year to expand DSA capacity, develop new services and reduce outsourcing...
inotiv-logo.png
Inotiv, Inc. Announces Plan to Insource North American Transportation Operations
06 déc. 2023 16h30 HE | Inotiv, Inc.
WEST LAFAYETTE, Ind., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug...
inotiv-logo.png
Inotiv, Inc. to Report Fiscal 2023 Fourth Quarter and Full Year Results and Host Conference Call on Monday, December 11, 2023
27 nov. 2023 16h05 HE | Inotiv, Inc.
WEST LAFAYETTE, Ind., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...
inotiv-logo.png
Inotiv Provides Business Updates and Upcoming Investor Conferences Update
13 nov. 2023 16h05 HE | Inotiv, Inc.
WEST LAFAYETTE, Ind., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and...